Institutional investors purchased a net $376.1 thousand shares of AVEO during the quarter ended December 2012 and now own 69.76% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
| Mutual fund holders | 35.13% |
| Other institutional | 34.63% |
| Individual stakeholders | 13.59% |